Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Third Harmonic Bio, Inc. (THRD)
NASDAQ:THRD
RESEARCH TOOLSreports
Holding THRD?
Track your performance easily
THRD Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.87 - $16.94
Previous Close$15.4
Volume110.29K
Average Volume (3M)194.41K
Market Cap
$693.90M
Enterprise Value$401.20M
Total Cash (Recent Filing)$296.10M
Total Debt (Recent Filing)$3.40M
Price to Earnings (P/E)―
Beta0.50
Next Earnings
Mar 26, 2025EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.96
Shares Outstanding45,058,413
10 Day Avg. Volume219,693
30 Day Avg. Volume194,410
Standard Deviation0.24
R-Squared0.23
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)2.30
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-21.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-7.60
Forecast
1Y Price Target
$20.00Price Target Upside32.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Third Harmonic Bio, Inc. News
PremiumCompany Announcements
Third Harmonic Bio Reports Q3 2024 Financial Results
PremiumCompany Announcements
Third Harmonic Bio Announces Executive Changes and Voting Results
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentTHB335 is a next-generation, oral WT-KIT inhibitor in early clinical development for mast-cell driven diseases.
Market PotentialCSU represents a large commercial opportunity with 400K patients in the US remaining uncontrolled on standard of care high dose antihistamines.
Safety ProfileExtensive preclinical work indicates THB335 is metabolically distinct, mitigating the risk of potential liver toxicity.
Bears Say
Clinical TrialsThird Harmonic discontinued its Phase 1b cold urticaria study with THB001 due to liver enzyme issues observed in participants.
Drug DevelopmentTHRD halted development of its first-generation small molecule THB001 after observing liver toxicity in a clinical study.
Financial PerformanceTHRD reported a net loss of $11 million.
---
Ownership Overview
37.67% Insiders
5.19% Mutual Funds
6.63% Other Institutional Investors
45.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
THRD FAQ
What was Third Harmonic Bio, Inc.’s price range in the past 12 months?
Third Harmonic Bio, Inc. lowest stock price was $5.87 and its highest was $16.94 in the past 12 months.
What is Third Harmonic Bio, Inc.’s market cap?
Currently, no data Available
When is Third Harmonic Bio, Inc.’s upcoming earnings report date?
Third Harmonic Bio, Inc.’s upcoming earnings report date is Mar 26, 2025 which is in 124 days.
How were Third Harmonic Bio, Inc.’s earnings last quarter?
Third Harmonic Bio, Inc. released its earnings results on Nov 07, 2024. The company reported -$0.33 earnings per share for the quarter, missing the consensus estimate of -$0.299 by -$0.031.
Is Third Harmonic Bio, Inc. overvalued?
According to Wall Street analysts Third Harmonic Bio, Inc.’s price is currently Undervalued.
Does Third Harmonic Bio, Inc. pay dividends?
Third Harmonic Bio, Inc. does not currently pay dividends.
What is Third Harmonic Bio, Inc.’s EPS estimate?
Third Harmonic Bio, Inc.’s EPS estimate is -$0.37.
How many shares outstanding does Third Harmonic Bio, Inc. have?
Third Harmonic Bio, Inc. has 45,058,414 shares outstanding.
What happened to Third Harmonic Bio, Inc.’s price movement after its last earnings report?
Third Harmonic Bio, Inc. reported an EPS of -$0.33 in its last earnings report, missing expectations of -$0.299. Following the earnings report the stock price went up 4.974%.
Which hedge fund is a major shareholder of Third Harmonic Bio, Inc.?
Among the largest hedge funds holding Third Harmonic Bio, Inc.’s share is RA Capital Management. It holds Third Harmonic Bio, Inc.’s shares valued at 26M.
---
Third Harmonic Bio, Inc. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$20.00 (32.98% Upside)
$20.00 (32.98% Upside)
Blogger Sentiment
Bullish
THRD Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $14.3M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
154.96%
12-Months-Change
Fundamentals
Return on Equity
-13.81%
Trailing 12-Months
Asset Growth
7.88%
Trailing 12-Months
Company Description
Third Harmonic Bio, Inc.
Third Harmonic Bio Inc is a clinical-stage company developing a novel oral approach to the treatment of severe allergy and inflammation. The company's lead product candidate, THB001, is a highly selective, oral small-molecule inhibitor of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival.
---
THRD Stock 12 Month Forecast
Average Price Target
$20.00
▲(32.98% Upside)
Technical Analysis
Adicet Bio
―
Iovance Biotherapeutics
―
Arcutis Biotherapeutics
―
Blueprint Medicines
―
Best Analysts Covering THRD
1 Year
1 Year Success Rate
6/7 ratings generated profit
1 Year Average Return
+38.21%
reiterated a buy rating 15 days ago
Copying Joseph Thome's trades and holding each position for 1 Year would result in 85.71% of your transactions generating a profit, with an average return of +38.21% per trade.
---